Brief: ProQR Announces Initial Pipeline Targets, Highlights Axiomer RNA Editing

ProQR Therapeutics NV

29/03/2023 16:07

March 29 (Reuters) - ProQR Therapeutics NV  PRQR.O :
    * PROQR THERAPEUTICS:AX-0810 FOR CHOLESTATIC DISEASES
TARGETING
NTCP & AX-1412 FOR CARDIOVASCULAR DISEASE TARGETING B4GALT1 AS
INITIAL PIPELINE PROGRAMS
    * PROQR THERAPEUTICS NV - CASH RUNWAY EXTENDED INTO MID-2026
FOLLOWING ELI LILLY MILESTONE RELATED TO PARTNERSHIP EXPANSION
    * PROQR THERAPEUTICS NV - INTENDS TO ADVANCE AX-1412
TARGETING
B4GALT1 TO EARLY CLINICAL PROOF OF CONCEPT STAGE, THEN WOULD
SEEK TO PARTNER THIS PROGRAM
    * PROQR THERAPEUTICS NV - EXPECTS TO ADVANCE AX-0810
TARGETING
NTCP AND AX-1412 TARGETING B4GALT1 INTO CLINICAL DEVELOPMENT IN
LATE 2024/EARLY 2025
    * PROQR THERAPEUTICS NV - WILL CONTINUE TO EXECUTE ON ITS
EXISTING
PARTNERSHIP WITH LILLY
    * PROQR THERAPEUTICS NV - SEEKING TO PARTNER ITS
OPHTHALMOLOGY
ASSETS (WHICH DO NOT UTILIZE AXIOMER TECHNOLOGY)
    * PROQR THERAPEUTICS NV - AXIOMER ACTIVITY DEMONSTRATED
ACROSS
MULTIPLE PRECLINICAL IN VITRO, ORGANOID, AND IN VIVO MODELS

Source text for Eikon:  ID:nGNX9fNYDj 
Further company coverage:  PRQR.O 

 ((Reuters.Briefs@thomsonreuters.com;))